PharmaResearch Co., Ltd. (214450.KQ)

KRW 259500.0

(2.77%)

Long Term Debt Summary of PharmaResearch Co., Ltd.

PharmaResearch Co., Ltd.'s latest annual long term debt in 2023 was 970.71 Million KRW , down -97.86% from previous year.
PharmaResearch Co., Ltd.'s latest quarterly long term debt in 2024 Q2 was 208.24 Million KRW , down -96.93% from previous quarter.
PharmaResearch Co., Ltd. reported annual long term debt of 45.35 Billion KRW in 2022, up 4.55% from previous year.
PharmaResearch Co., Ltd. reported annual long term debt of 43.38 Billion KRW in 2021, up 312.99% from previous year.
PharmaResearch Co., Ltd. reported quarterly long term debt of 208.24 Million KRW for 2024 Q2, down -96.93% from previous quarter.
PharmaResearch Co., Ltd. reported quarterly long term debt of 970.71 Million KRW for 2023 FY, down -97.86% from previous quarter.

Annual Long Term Debt Chart of PharmaResearch Co., Ltd. (2023 - 2015)

Historical Annual Long Term Debt of PharmaResearch Co., Ltd. (2023 - 2015)

Year	Long Term Debt	Long Term Debt Growth
2023	970.71 Million KRW	-97.86%
2022	45.35 Billion KRW	4.55%
2021	43.38 Billion KRW	312.99%
2020	10.5 Billion KRW	-36.32%
2019	16.49 Billion KRW	-4.89%
2018	17.34 Billion KRW	0.0%
2017	- KRW	0.0%
2016	- KRW	-100.0%
2015	5.4 Billion KRW	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	6.78 Billion KRW	3412.66%
2024 Q2	208.24 Million KRW	-96.93%
2023 FY	970.71 Million KRW	-97.86%
2023 Q2	32.06 Billion KRW	-30.73%
2023 Q1	46.29 Billion KRW	2.07%
2023 Q3	31.33 Billion KRW	-2.29%
2023 Q4	970.71 Million KRW	-96.9%
2022 Q3	44.93 Billion KRW	1.69%
2022 Q4	45.35 Billion KRW	0.95%
2022 FY	45.35 Billion KRW	4.55%
2022 Q2	44.18 Billion KRW	0.78%
2022 Q1	43.84 Billion KRW	1.06%
2021 FY	43.38 Billion KRW	312.99%
2021 Q1	627.41 Million KRW	-95.11%
2021 Q4	43.38 Billion KRW	13042.21%
2021 Q3	330.11 Million KRW	-30.41%
2021 Q2	474.38 Million KRW	-24.39%
2020 Q3	15.81 Billion KRW	0.74%
2020 FY	10.5 Billion KRW	-36.32%
2020 Q4	12.82 Billion KRW	-18.88%
2020 Q1	15.58 Billion KRW	-10.59%
2020 Q2	15.69 Billion KRW	0.71%
2019 Q3	16.29 Billion KRW	1.25%
2019 FY	16.49 Billion KRW	-4.89%
2019 Q4	17.43 Billion KRW	7.01%
2019 Q2	16.09 Billion KRW	-7.36%
2019 Q1	17.36 Billion KRW	0.16%
2018 Q1	28.65 Billion KRW	0.0%
2018 FY	17.34 Billion KRW	0.0%
2018 Q4	17.34 Billion KRW	0.17%
2018 Q3	17.31 Billion KRW	0.17%
2018 Q2	17.28 Billion KRW	-39.68%
2017 Q3	- KRW	0.0%
2017 Q2	- KRW	0.0%
2017 Q1	- KRW	0.0%
2017 Q4	- KRW	0.0%
2017 FY	- KRW	0.0%
2016 Q3	- KRW	0.0%
2016 Q1	- KRW	-100.0%
2016 Q4	- KRW	0.0%
2016 FY	- KRW	-100.0%
2015 FY	5.4 Billion KRW	0.0%
2015 Q4	5.4 Billion KRW	0.0%

Peer Long Term Debt Comparison of PharmaResearch Co., Ltd.

Name	Long Term Debt	Long Term Debt Difference
HLB Co., Ltd.	17.93 Billion KRW	94.587%
iNtRON Biotechnology, Inc.	258.29 Million KRW	-275.817%
BINEX Co., Ltd.	5.57 Billion KRW	82.599%
Bioneer Corporation	12.5 Billion KRW	92.234%
Anterogen.Co.,Ltd.	- KRW	-Infinity%
MEDIPOST Co., Ltd.	6.99 Billion KRW	86.123%
CrystalGenomics, Inc.	29.88 Billion USD	96.752%
Helixmith Co., Ltd	151.68 Million KRW	-539.977%
Chabiotech Co.,Ltd.	95.06 Billion KRW	98.979%
Medy-Tox Inc.	1.22 Billion KRW	20.812%
Peptron, Inc.	4.5 Billion KRW	78.429%
Amicogen, Inc.	70.65 Billion KRW	98.626%
Genexine, Inc.	22.68 Billion KRW	95.72%
HLB Therapeutics Co.,Ltd.	1.84 Billion KRW	47.249%
LegoChem Biosciences, Inc.	528.37 Million KRW	-83.718%
ALTEOGEN Inc.	1.24 Billion KRW	22.296%
SillaJen, Inc.	8.13 Billion KRW	88.069%
JETEMA, Co., Ltd.	60 Billion KRW	98.382%
OliX Pharmaceuticals,Inc	35.36 Billion KRW	97.255%
Genomictree Inc.	97.51 Million KRW	-895.447%
MedPacto, Inc.	1.68 Billion KRW	42.457%
D&D Pharmatech	5.12 Billion KRW	81.043%
EASY BIO,Inc.	30 Billion KRW	96.764%
GI Innovation, Inc.	2.9 Billion KRW	66.573%